| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/11/2007 | CA2603044A1 Alpha-2 adrenergic agonists for the treatment of pain |
| 01/10/2007 | EP1741792A1 Novel ligand of g-protein-conjugated receptor protein and use thereof |
| 01/10/2007 | EP1741783A1 Human antiamyloid beta peptide antibody and antibody fragment thereof |
| 01/10/2007 | EP1741782A2 Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
| 01/10/2007 | EP1741781A2 RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| 01/10/2007 | EP1741780A2 High affinity oligonucleotide ligands to growth factors |
| 01/10/2007 | EP1741779A2 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity |
| 01/10/2007 | EP1741718A2 Expression of lipoproteins |
| 01/10/2007 | EP1741717A1 Metal nanostructures and pharmaceutical compositions |
| 01/10/2007 | EP1741716A1 Process for producing pentacyclic taxane |
| 01/10/2007 | EP1741715A1 Epothilone derivatives and their synthesis and use |
| 01/10/2007 | EP1741714A1 Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient |
| 01/10/2007 | EP1741713A2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 01/10/2007 | EP1741712A2 Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol |
| 01/10/2007 | EP1741710A1 Pyrrolidine derivative |
| 01/10/2007 | EP1741709A1 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| 01/10/2007 | EP1741708A1 Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| 01/10/2007 | EP1741704A1 Method for increasing specific surface area of slightly soluble drug |
| 01/10/2007 | EP1741703A1 Pyridone derivative |
| 01/10/2007 | EP1741702A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| 01/10/2007 | EP1741697A1 Crystal comprising (2r)-2-propyloctoic acid and amine |
| 01/10/2007 | EP1741447A2 Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| 01/10/2007 | EP1741446A2 Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| 01/10/2007 | EP1741445A2 Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| 01/10/2007 | EP1741441A1 Bone densifying agent characterized by use of cathepsin k inhibitor with pth |
| 01/10/2007 | EP1741439A1 Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
| 01/10/2007 | EP1741435A1 Oral modified-release lozenges and their preparation method |
| 01/10/2007 | EP1741434A1 The use of timosaponin bii in preparing the drug or produce of preventing and treating stroke |
| 01/10/2007 | EP1741433A1 Pharmaceutical composition comprising an androgen |
| 01/10/2007 | EP1741432A1 The tyrosin kinase inhibitor Imatinib for the treatment of hypertension |
| 01/10/2007 | EP1741431A1 The combination for treating hyperlipemia |
| 01/10/2007 | EP1741430A1 Remedy for psychoneurotic diseases |
| 01/10/2007 | EP1741429A2 Processes for preparing torsemide |
| 01/10/2007 | EP1741428A2 Cell adhesion inhibitors |
| 01/10/2007 | EP1741427A1 Pharmaceutical composition comprising simvastatin and ezetimibe |
| 01/10/2007 | EP1741426A2 Melt-extruded orally administrable opioid formulations |
| 01/10/2007 | EP1741425A2 Novel antiviral pharmaceutical composition |
| 01/10/2007 | EP1741424A2 Solid pharmaceutical dispersions with enhanced bioavailabilty |
| 01/10/2007 | EP1740710A1 Labeling of rapamycin using rapamycin-specific methylases |
| 01/10/2007 | EP1740599A1 Anthracycline derivatives |
| 01/10/2007 | EP1740595A1 Polycyclic macrolactones |
| 01/10/2007 | EP1740594A1 Clopidogrel salt and polymorphic forms thereof |
| 01/10/2007 | EP1740591A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 01/10/2007 | EP1740590A1 PYRAZOLO [3,4- b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS |
| 01/10/2007 | EP1740589A1 Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments |
| 01/10/2007 | EP1740587A2 Selective antagonists of a-2a- adenosine receptors |
| 01/10/2007 | EP1740586A2 Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one |
| 01/10/2007 | EP1740585A1 Enantiomer-pure hexahydro- pyrrolocyclopenta- pyridine derivatives |
| 01/10/2007 | EP1740584A1 Fused quinoline derivative and use thereof |
| 01/10/2007 | EP1740583A1 Oxadiazolone derivatives as ppar delta agonists |
| 01/10/2007 | EP1740582A1 Acyl dihydro pyrrole derivatives as hcv inhibitors |
| 01/10/2007 | EP1740580A2 Crystalline 2-amino-3-cyanoquinoline derivatives , process of their preparation and pharmaceutical compositions containing them |
| 01/10/2007 | EP1740579A1 Tricyclic pyrazole kinase inhibitors |
| 01/10/2007 | EP1740578A1 4- 2- (cycloalkylamino) pyrimidin-4-yl ] - (phenyl) - imidazolin-2- one derivatives as p38 map- kinase inhibitors for the treatment of inflammatory diseases |
| 01/10/2007 | EP1740577A2 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments |
| 01/10/2007 | EP1740576A1 Novel piperidine substituted diaminothiazoles |
| 01/10/2007 | EP1740575A2 Pyrrolidine derivatives useful as bace inhibitors |
| 01/10/2007 | EP1740573A1 Amides as bace inhibitors |
| 01/10/2007 | EP1740572A1 Novel alkyne compounds with an mch-antagonistic action and medicaments containing said compounds |
| 01/10/2007 | EP1740570A2 Novel gamma secretase inhibitors |
| 01/10/2007 | EP1740569A1 Imidazole derivatives used as tafia inhibitors |
| 01/10/2007 | EP1740568A2 Benzofuran and benzothiophene derivatives useful for the treatment of cardiovascular disease. |
| 01/10/2007 | EP1740566A1 Hki10311129, novel antibiotic, method for producing the same and the use thereof |
| 01/10/2007 | EP1740563A2 Mycophenolate mofetil impurity |
| 01/10/2007 | EP1740561A2 Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them |
| 01/10/2007 | EP1740560A1 Tri(cyclo) substituted amide compounds |
| 01/10/2007 | EP1740559A1 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| 01/10/2007 | EP1740558A1 Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors |
| 01/10/2007 | EP1740557A1 Urea derivatives as antagonists of the vanilloid receptor (vr1) |
| 01/10/2007 | EP1740556A1 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses |
| 01/10/2007 | EP1740553A1 Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors |
| 01/10/2007 | EP1740552A1 2- ( arylalkoxy ) -1- phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors |
| 01/10/2007 | EP1740551A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| 01/10/2007 | EP1740550A1 Sulphur-linked imidazole compounds for the treament of hiv |
| 01/10/2007 | EP1740549A2 Novel imidazoles |
| 01/10/2007 | EP1740548A1 Novel phenantridine analogues and their uses as inhibitors of hyperproliferation of t cells and/or keratinocytes |
| 01/10/2007 | EP1740547A1 Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| 01/10/2007 | EP1740541A2 Therapeutic formulations of desoxyepothilones |
| 01/10/2007 | EP1740540A1 Phenyl acetamides |
| 01/10/2007 | EP1740538A2 Bicyclic heterocycles useful as serine protease inhibitors |
| 01/10/2007 | EP1740535A1 Thio-substituted methanesulfinyl derivatives |
| 01/10/2007 | EP1740533A1 Androgen modulators |
| 01/10/2007 | EP1740532A2 Hydrazide-containing cftr inhibitor compounds and uses thereof |
| 01/10/2007 | EP1740531A1 Indene derivatives and process for the preparation thereof |
| 01/10/2007 | EP1740254A2 Systems and methods for administering a medical regimen |
| 01/10/2007 | EP1740225A2 Contrast agents for myocardial perfusion imaging |
| 01/10/2007 | EP1740224A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use |
| 01/10/2007 | EP1740219A2 Medical device with coating for capturing genetically-altered cells and methods of using same |
| 01/10/2007 | EP1740214A2 Method of stabilizing disordered cefovecin sodium salt |
| 01/10/2007 | EP1740212A2 Pharmaceutical compositions comprising beta-carboline derivatives and use thereof for the treatment of cancer |
| 01/10/2007 | EP1740211A2 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| 01/10/2007 | EP1740196A1 Compositions and method for alleviating inflammation and oxidative stress in a mammal |
| 01/10/2007 | EP1740193A2 Macromolecule-containing sustained release intraocular implants and related methods |
| 01/10/2007 | EP1740192A2 Method for stimulating the immune, inflammatory or neuroprotective response |
| 01/10/2007 | EP1740191A1 Use of equol for treating skin diseases |
| 01/10/2007 | EP1740190A1 Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro |
| 01/10/2007 | EP1740189A1 Lung surfactant supplements |
| 01/10/2007 | EP1740188A1 Use of ciclesonide for the treatment of respiratory diseases in a smoking patient |
| 01/10/2007 | EP1740187A1 Macular edema patient selection method and treatment with eye implant comprising a steroid |
| 01/10/2007 | EP1740186A1 Biodegradable intraocular implants containing prostamides |